Actively Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-05-30
60
Participants Needed
3
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.
CONDITIONS
Official Title
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Histologically confirmed esophageal squamous cell carcinoma
- Locally advanced ESCC diagnosed by CT or endoscopic ultrasonography, staged by AJCC 8th edition
- ECOG performance status score of 0 or 1
- Normal main organ and bone marrow function, including specified blood counts and liver and kidney function tests
You will not qualify if you...
- Presence of other primary malignant tumors except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix
- Prior treatments for esophageal cancer
- Distant or hematogenous metastases beyond supraclavicular lymph nodes, including multiple lymph node, bone, brain, lung, liver metastases, or malignant effusions
- Esophageal perforation or high risk of perforation
- Tumor invading near large blood vessels with bleeding risk
- Active infections such as tuberculosis or hepatitis
- Contraindications to immunotherapy
- Pregnant or lactating women or women not using reliable contraception
- Serious cardiovascular diseases including uncontrolled heart failure, coronary disease, cardiomyopathy, arrhythmia, uncontrolled hypertension, or recent myocardial infarction
- Other uncontrolled acute or chronic diseases such as hypertension and diabetes
- Any condition or reason judged by the researcher to prevent continuation of drug treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Anyang Cancer Hospital
Anyang, Henan, China
Not Yet Recruiting
2
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Not Yet Recruiting
3
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China, 100021
Actively Recruiting
Research Team
X
Xin Wang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here